Chemogenics BioPharma

Executive Summary

Chemogenics BioPharma is a privately held drug discovery research and service organization headquartered in Durham, North Carolina. Founded in 2017, the company positions itself as a one-stop partner for pharmaceutical, biotechnology, academic, and government institutions, offering high-quality and cost-effective solutions across multiple stages of drug discovery. With a focus on small molecules and oncology, Chemogenics provides services ranging from hit identification to lead optimization, leveraging its expertise to accelerate preclinical development for clients globally. As a contract research organization (CRO) in the competitive Research Triangle ecosystem, the company differentiates through integrated, end-to-end capabilities and a commitment to economic feasibility. While the company operates in a services model rather than as a drug developer, its growth is tied to sustained demand for outsourced R&D and its ability to secure repeat business from biopharma clients.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnership with a mid-sized biotech firm60% success
• Q4 2026Expansion of service capabilities into new therapeutic areas or modalities50% success
• TBDPublication of case studies demonstrating successful client programs70% success